Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common malignant lymphoma in China, which mostly starting from the lymph nodes. The studies find that the expression of NLRC5, member of nucleotide-binding oligomerization domain-like receptor (NLR) family, is evident in the lymphoid cells, which is likely to be an important basis for lymphocyte tumorigenesis. NLRC5 can block the nuclear factor-κB (NF-κB), a core component of signal transduction pathway, and affect the development of tumor. While continuing activation of NF-κB is a necessary condition for DLBCL cell survival. Therefore, NLRC5 is likely to inhibit excessive inflammation, thereby inhibiting the function of DLBCL, which promises to be a new target for immunotherapy treatment of DLBCL. Key words: Lymphoma, large B-cell, diffuse; NF-kappaB; Genes, MHC class Ⅰ; NLRC5

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.